tetano
Editor, Senior Moderator
Ann Med Surg (Lond)
. 2022 Dec;84:104929.
doi: 10.1016/j.amsu.2022.104929. Epub 2022 Nov 19.
Anticoagulation failure in pulmonary thromboembolism in COVID-19 pneumonia despite prolonged anticoagulation: A case series
Prakash Sapkota[SUP] 1 [/SUP], Ashish Tamang[SUP] 2 [/SUP], Sadikshya Bhandari[SUP] 1 [/SUP], Yadvinder Singh[SUP] 1 [/SUP], Rohit Bhasink Shrestha[SUP] 2 [/SUP], Robin Man Karmacharya[SUP] 3 [/SUP], Satish Vaidya[SUP] 3 [/SUP], Swechha Bhatt[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Moderate to severely ill patients diagnosed with Coronavirus disease 2019 (COVID-19) pneumonia develop a series of complications and less frequently, we might witness cases of Pulmonary Thromboembolism (PE)-refractory to the standard treatment with Low Molecular Weight Heparin (LMWH). The aim of this case series is to report the presentation and management of pulmonary thromboembolism secondary to COVID-19 pneumonia.
Method: We report a case series of seven cases aged 40-70 who were presented in Dhulikhel Hospital with COVID-19 symptoms in different stages. The case details were extracted from their medical reports of the hospital. The written informed ethical consents were obtained from all the cases and their voluntary participation was assured.
Outcome: The cases in the case series admitted with COVID-19 pneumonia, after diagnostic investigation (Chest x-ray, HRCT, CTPA) were suggestive of COVID-19 Pneumonia with ARDS and pulmonary thromboembolism. The cases received rivaroxaban, a newer anticoagulant-15 mg twice daily for 21 days and after discharge, they were asked to continue once daily doses for 9 weeks. Significant improvement was witnessed, with the presence of additional intervention including rehabilitative chest exercises.
Conclusion: Pulmonary thromboembolism secondary to COVID-19 pneumonia is a life-threatening condition. Rivaroxaban is seen to be very effective in the management of this condition when an anticoagulation failure occurs even after the therapeutic dose of low molecular weight heparin. Future studies may require more scientific investigations to prevent complications even in the early stages of COVID-19.
Keywords: Anticoagulant; COVID-19; Case series; Pneumonia; Pulmonary thromboembolism.
. 2022 Dec;84:104929.
doi: 10.1016/j.amsu.2022.104929. Epub 2022 Nov 19.
Anticoagulation failure in pulmonary thromboembolism in COVID-19 pneumonia despite prolonged anticoagulation: A case series
Prakash Sapkota[SUP] 1 [/SUP], Ashish Tamang[SUP] 2 [/SUP], Sadikshya Bhandari[SUP] 1 [/SUP], Yadvinder Singh[SUP] 1 [/SUP], Rohit Bhasink Shrestha[SUP] 2 [/SUP], Robin Man Karmacharya[SUP] 3 [/SUP], Satish Vaidya[SUP] 3 [/SUP], Swechha Bhatt[SUP] 2 [/SUP]
Affiliations
- PMID: 36439890
- PMCID: PMC9675080
- DOI: 10.1016/j.amsu.2022.104929
Abstract
Introduction: Moderate to severely ill patients diagnosed with Coronavirus disease 2019 (COVID-19) pneumonia develop a series of complications and less frequently, we might witness cases of Pulmonary Thromboembolism (PE)-refractory to the standard treatment with Low Molecular Weight Heparin (LMWH). The aim of this case series is to report the presentation and management of pulmonary thromboembolism secondary to COVID-19 pneumonia.
Method: We report a case series of seven cases aged 40-70 who were presented in Dhulikhel Hospital with COVID-19 symptoms in different stages. The case details were extracted from their medical reports of the hospital. The written informed ethical consents were obtained from all the cases and their voluntary participation was assured.
Outcome: The cases in the case series admitted with COVID-19 pneumonia, after diagnostic investigation (Chest x-ray, HRCT, CTPA) were suggestive of COVID-19 Pneumonia with ARDS and pulmonary thromboembolism. The cases received rivaroxaban, a newer anticoagulant-15 mg twice daily for 21 days and after discharge, they were asked to continue once daily doses for 9 weeks. Significant improvement was witnessed, with the presence of additional intervention including rehabilitative chest exercises.
Conclusion: Pulmonary thromboembolism secondary to COVID-19 pneumonia is a life-threatening condition. Rivaroxaban is seen to be very effective in the management of this condition when an anticoagulation failure occurs even after the therapeutic dose of low molecular weight heparin. Future studies may require more scientific investigations to prevent complications even in the early stages of COVID-19.
Keywords: Anticoagulant; COVID-19; Case series; Pneumonia; Pulmonary thromboembolism.